ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 135,000 common shares to three new employees on March 2, 2026 as inducements for employment. The Compensation Committee approved the awards under the company's Inducement Plan relying on the NYSE employment inducement exemption.

The awards vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.

News Market Reaction – ADCT

-3.11%

-3.11% Session close to close

In the Mar 3 session, ADCT declined 3.11%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details option grants for 135,000 shares to three new employees under ADC Therapeu...

Analysis

This announcement details option grants for 135,000 shares to three new employees under ADC Therapeutics’ Inducement Plan, vesting over four years. It follows earlier inducement awards and recent corporate milestones, including preliminary 2025 revenue and cash updates and an amended royalty financing agreement. Investors may focus on how recurring equity-based compensation interacts with existing large shareholders, the effective S-3/A shelf registration, and upcoming clinical and financial disclosures when assessing longer-term implications.

Key Figures

Inducement options: 135,000 shares Employee count: 3 employees Initial vesting: 25% +3 more

6 metrics

Inducement options 135,000 shares Options granted to three new employees on March 2, 2026

Employee count 3 employees Recipients of inducement option grants

Initial vesting 25% Portion vesting on first anniversary of grant date

Ongoing vesting rate 1/48th monthly Monthly vesting after first anniversary until full vesting

Full vesting period 4 years Entire option award vested by fourth anniversary

Shelf expenses $71,341.46 Estimated total offering-related expenses in S-3/A amendment

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 24	Investor conferences	Neutral	-0.5%	Announced participation in March 2026 healthcare investor conferences and webcasts.
Feb 23	Financing amendment	Neutral	+7.6%	Amended HealthCare Royalty agreement with new change-of-control terms and warrants.
Feb 02	Inducement grants	Neutral	+0.0%	Granted options for 308,000 shares to new employees under Inducement Plan.
Jan 08	Prelim results	Positive	+2.5%	Preliminary 2025 revenue, cash runway to 2028, and strong LOTIS-7 efficacy data.
Jan 08	Prelim results	Positive	+2.5%	Repeat preliminary 2025 financial and clinical update with same key metrics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company news, including financing changes and corporate updates, has generally led to modest single-digit price moves, with one larger positive reaction to the amended royalty agreement.

Recent Company History

Over the last few months, ADCT has reported several notable updates. On January 8, 2026, it released preliminary 2025 revenue and cash figures along with clinical progress, and the stock moved +2.52%. On February 2, 2026, it announced inducement option grants, which saw a 0% next-day move. An amended HealthCare Royalty financing on February 23, 2026 coincided with a +7.56% reaction. Participation in March investor conferences on February 24, 2026 led to a small -0.45% move. Today’s additional inducement grants fit this pattern of incremental corporate updates.

Key Terms

antibody drug conjugates, options, employment inducement exemption

3 terms

antibody drug conjugates medical

"a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

options financial

"the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares"

Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.

View in glossary

employment inducement exemption regulatory

"The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08."

An employment inducement exemption is a regulatory allowance that lets a public company grant stock or option awards to a new hire without getting prior shareholder approval, provided the awards are given solely to attract or retain that employee and meet specific limits and rules. Investors care because these one-off grants increase the total number of shares available and can dilute existing ownership and earnings per share, much like adding more slices to an already shared pie.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares to three new employees on March 2, 2026 (each, a "Grant").

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: changes to the preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents as of December 31, 2025; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability to grow ZYNLONTA^® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302697236.html

SOURCE ADC Therapeutics SA

FAQ

What did ADC Therapeutics (ADCT) announce on March 2, 2026 about employee option grants?

ADC Therapeutics granted an aggregate of 135,000 stock options to three new employees on March 2, 2026. According to the company, the grants were made as material inducements under its Inducement Plan and approved by the Compensation Committee.

How do the ADCT inducement grants vest for the options awarded on March 2, 2026?

The options vest 25% after one year, then 1/48th monthly, fully vesting at four years. According to the company, vesting is subject to continued employment with ADC Therapeutics.

Why did ADC Therapeutics (ADCT) rely on the NYSE inducement exemption for these grants?

ADC Therapeutics relied on the NYSE employment inducement exemption to issue the awards outside prior shareholder-approved plans. According to the company, the exemption permits such inducement grants under Listed Company Manual Rule 303A.08.

How many employees received ADCT inducement grants and what was the aggregate size?

Three new employees received grants totaling 135,000 options on March 2, 2026. According to the company, each grant was offered as a material inducement to the recipients' employment.

Will the ADCT inducement option grants dilute existing shareholders immediately?

The grants are options and do not cause immediate share issuance or dilution until exercised. According to the company, the awards grant rights to purchase shares subject to vesting and exercise conditions.